| Literature DB >> 23938286 |
Jessica S Rowlan1, Qiongzhen Li, Ani Manichaikul, Qian Wang, Alan H Matsumoto, Weibin Shi.
Abstract
BACKGROUND: C3H/HeJ (C3H) mice are extremely resistant to atherosclerosis, especially males. To understand the underlying genetic basis, we performed quantitative trait locus (QTL) analysis on a male F2 (the second generation from an intercross between 2 inbred strains) cohort derived from an intercross between C3H and C57BL/6 (B6) apolipoprotein E-deficient (Apoe(-/-)) mice. METHODS ANDEntities:
Keywords: atherosclerosis; cholesterol; mapping; quantitative trait loci; sex
Mesh:
Substances:
Year: 2013 PMID: 23938286 PMCID: PMC3828785 DOI: 10.1161/JAHA.113.000260
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1.Frequency distributions of atherosclerotic lesion sizes and plasma lipid levels in 246 male F2 mice after being fed a Western diet for 5 weeks. The F2 progeny was generated from an intercross between B6.Apoe−/− and C3H.Apoe−/− mice. Note that the unit for untransformed atherosclerotic lesion sizes is “μm2×1000,” whereas the unit for LN‐transformed atherosclerotic lesion sizes is “μm2.” LN indicates natural logs.
Figure 2.Genomewide QTL analysis to search for loci influencing atherosclerotic lesion sizes in male F2 mice. Chromosomes 1 through 20 are represented numerically on the x axis. The relative width of the space allotted for each chromosome reflects the number of microsatellite markers typed for that chromosome. The y axis represents the LOD score. Two horizontal dashed lines denote genomewide thresholds for suggestive (P=0.63) and significant (P=0.05) linkage. The top panel shows a genomewide scan for atherosclerotic lesions using the nonparametric mode, and the bottom panel shows an autosome scan for atherosclerotic lesions using the parametric mode. For the latter scan, the X chromosome was not included due to a strong biased influence from the chromosome. QTL indicates quantitative trait locus; LOD, logarithm of odds.
Significant and Suggestive QTLs for Atherosclerosis and Plasma Lipid Levels in Male F2 Mice Derived from B6.Apoe−/− and C3H.Apoe−/− Mice
| Locus Name | Chr | Trait | LOD | Peak, cM | 95% CI | High Allele | Mode of Inheritance | |
|---|---|---|---|---|---|---|---|---|
|
| 2 | Lesion (nonparametric) |
| 100.5 | 90.2 to 103.8 | 0.041 | C3H | Recessive |
|
| 4 | Lesion (nonparametric) |
| 31.6 | 23.6 to 77.6 | 0.022 | B6 | Dominant |
|
| 4 | Lesion (nonparametric) | 2.14 | 77.6 | 63 to 82.6 | … | B6 | Dominant |
|
| 7 | Lesion (nonparametric) | 2.25 | 59.1 | 47.1 to 73.0 | 0.489 | B6 | Dominant |
|
| 9 | Lesion (nonparametric) |
| 44.2 | 40.2 to 48.2 | 0.0001 | B6 | Additive |
|
| 15 | Lesion (nonparametric) |
| 37.8 | 21.8 to 43.8 | 0.0001 | C3H | Additive |
|
| 1 | Lesion (parametric) | 2.34 | 39.2 | 3.7 to 91.7 | 0.385 | B6 | Dominant |
|
| 1 | Lesion (parametric) | 2.10 | 78 | 66 to 93 | … | B6 | Dominant |
|
| 2 | Lesion (parametric) | 3.24 | 100.5 | 88.2 to 103.8 | 0.054 | C3H | Recessive |
|
| 4 | Lesion (parametric) |
| 33.6 | 25.6 to 82.6 | 0.047 | B6 | Heterosis |
|
| 4 | Lesion (parametric) | 2.65 | 75.6 | 67.6 to 82.6 | … | B6 | Dominant |
|
| 7 | Lesion (parametric) | 2.77 | 61.1 | 51.1 to 73.0 | 0.175 | B6 | Dominant |
|
| 9 | Lesion (parametric) |
| 46.2 | 40.2 to 58.2 | 0.019 | B6 | Additive |
|
| 15 | Lesion (parametric) |
| 25.8 | 15.2 to 39.8 | 0.005 | C3H | Additive |
|
| 1 | HDL |
| 67.71 | 65.67 to 73.67 | 0.0001 | C3H | Additive |
|
| 8 | HDL | 2.11 | 17.7 | 13.7 to 45.7 | 0.617 | Heterosis | |
|
| 9 | HDL | 3.04 | 20.2 | 0 to 34 | … | C3H | Additive |
|
| 9 | HDL |
| 43.91 | 18.24 to 48.24 | 0.054 | C3H | Additive |
|
| 12 | HDL | 2.81 | 12.04 | 10.04 to 44.04 | 0.228 | C3H | Heterosis |
|
| 13 | HDL | 3.05 | 64.72 | 21.99 to 64.72 | 0.145 | C3H | Dominant |
|
| 1 | Non‐HDL |
| 75.67 | 67.71 to 85.67 | 0.002 | C3H | Additive |
|
| 4 | Non‐HDL | 2.51 | 13.55 | 13.55 to 57.55 | 0.323 | B6 | Additive |
|
| 12 | Non‐HDL |
| 54.04 | 30.04 to 58.04 | 0.0001 | B6 | Dominant |
|
| 14 | Non‐HDL | 2.24 | 29.37 | 19.37 to 35.37 | 0.488 | C3H | Additive |
|
| 15 | Non‐HDL | 2.43 | 51.82 | 3.82 to 53.94 | 0.367 | C3H | Recessive |
|
| X | Non‐HDL | 2.22 | 24.59 | 20.59 to 58.59 | 0.511 | ||
|
| 1 | Triglyceride |
| 77.67 | 73.67 to 85.67 | 0.0001 | C3H | Additive |
|
| 2 | Triglyceride | 2.62 | 49.35 | 24.23 to 58.23 | 0.305 | C3H | Dominant |
|
| 16 | Triglyceride | 2.51 | 9.66 | 9.66 to 35.66 | 0.355 | B6 | Dominant |
QTL indicates quantitative trait locus; Chr, chromosome; LOD, logarithm of odds.
LOD scores were obtained from genomewide QTL analysis using J/qtl software. The significant LOD scores are highlighted in bold. The suggestive and significant LOD score thresholds were determined by 1000 permutation tests for each trait. Suggestive and significant LOD scores were 2.045 and 3.362 for atherosclerotic lesion size (nonparametric), 1.986 and 3.277 for natural log–transformed lesion sizes (parametric), 2.123 and 3.559 for HDL cholesterol, 2.087 and 3.49 for non‐HDL cholesterol, and 2.12 and 3.432 for triglycerides, respectively.
The 95% CI in cM defined by a whole genome QTL scan.
The P values reported represent the level of genomewide significance as they were generated by J/qtl basedon genomewide permutation tests.
High allele—the allele with a larger allelic effect at the peak marker of a QTL.
Mode of inheritance was defined according to allelic effect at the nearest marker of a QTL: dominant, a heterozygous allele produced the same phenotypic effect as a homozygous allele; additive, a heterozygous allele produced a phenotypic effect between the effect of the 2 homozygous alleles; recessive, an allele only expressed a phenotypic effect in the homozygous condition; and heterosis, a heterozygous allele produced a phenotypic effect exceeding the effect of the 2 homozygous alleles.
Effects of B6 (B) and C3H (C) Alleles in Different QTLs on Atherosclerosis and Plasma Lipids in the Intercross Between B6.Apoe−/− and C3H.Apoe−/− Mouse Strains
| Locus Namea | Chr | Trait | LOD | Peak, cM | Closest Marker | BB | BC | CC | |
|---|---|---|---|---|---|---|---|---|---|
|
| 2 | Lesion (nonparametric) |
| 100.5 | D2Mit148 | 12 595±12 897 (n=73) | 10 848±10 165 (n=99) | 28 271±36 479 (n=56) | 1.8E−06 |
|
| 4 | Lesion (nonparametric) |
| 31.6 | D4Mit139 | 15 296±13 347 (n=59) | 16 945±22 166 (n=104) | 12 520±24 876 (n=73) | 0.396 |
|
| 4 | Lesion (nonparametric) | 2.14 | 77.6 | D4Mit33 | 15 861±24 952 (n=53) | 17 479±23 433 (n=118) | 10 616±12 244 (n=59) | 0.136 |
|
| 7 | Lesion (nonparametric) | 2.25 | 59.1 | D7Mit330 | 17 873±27 165 (n=56) | 16 152±20 439 (n=118) | 11 153±16 419 (n=60) | 0.198 |
|
| 9 | Lesion (nonparametric) |
| 44.2 | D9Mit236 | 22 162±22 430 (n=54) | 15 020±20 472 (n=120) | 10 123±20 992 (n=63) | 9.26E−03 |
|
| 15 | Lesion (nonparametric) |
| 37.8 | D15Mit188 | 9386±11 194 (n=48) | 14 341±23 011 (n=120) | 24 495±25 337 (n=50) | 1.95E−03 |
|
| 1 | Lesion (parametric) | 2.34 | 39.2 | D1MIT161 | 16 369±17 243 (n=53) | 16 027±22 747 (n=121) | 13 748±22 869 (n=58) | 0.765 |
|
| 1 | Lesion (parametric) | 2.1 | 78 | D1Mit270 | 17 752±24 695 (n=64) | 16 318±23 341 (n=102 | 11 913±14 121 (n=67) | 0.261 |
|
| 2 | Lesion (parametric) | 3.24 | 100.5 | D2Mit148 | 12 595±12 897 (n=74) | 10 848±10 165 (n=99) | 28 271±36 479 (n=56) | 1.8E−06 |
|
| 4 | Lesion (parametric) |
| 33.6 | D4Mit178 | 14 252±12 034 (n=56) | 19 297±28 313 (n=107) | 10 376±12 777 (n=69) | 2.41E−02 |
|
| 4 | Lesion (parametric) | 2.65 | 75.6 | D4Mit33 | 15 861±24 952 (n=53) | 17479±23433 (n=118) | 10 616±12 244 (n=59) | 0.136 |
|
| 7 | Lesion (parametric) | 2.77 | 61.1 | D7Mit330 | 17 873±27 165 (n=56) | 16152±20439 (n=118) | 11 153±16 419 (n=60) | 0.198 |
|
| 9 | Lesion (parametric) |
| 46.2 | D9Mit236 | 22 162±22 430 (n=54) | 15 020±20 472 (n=120 | 10 123±20 992 (n=63) | 9.26E−03 |
|
| 15 | Lesion (parametric) |
| 25.8 | D15Mit143 | 9107±10943 (n=47) | 14 181±21 364 (n=127) | 22 794±25 419 (n=62) | 2.41E−03 |
|
| 1 | HDL |
| 67.71 | D1Mit425 | 64.8±45.3 (n=63) | 107.1±61.3 (n=113) | 114.1±66.7 (n=55) | 2.9E−06 |
|
| 8 | HDL | 2.11 | 17.7 | D8Mit191 | 81.0±53.3 (n=56) | 107.9±66.8 (n=134) | 83.5±49.3 (n=43) | 6.5E−03 |
|
| 9 | HDL | 3.04 | 0 to 34 | D9Mit297 | 81.1±53.8 (n=65) | 95.0±62.8 (n=105) | 116.2±63.8 (n=64) | 4.80E−03 |
|
| 9 | HDL |
| 43.91 | D9Mit236 | 73.2±48.7 (n=55) | 95.8±60.6 (n=120) | 120.2±66.7 (n=61) | 1.8E−04 |
|
| 12 | HDL | 2.81 | 12.04 | D12Mit84 | 77.7±52.5 (n=60) | 112.3±65.5 (n=98) | 92.8±60.6 (n=73) | 2.1E−03 |
|
| 13 | HDL | 3.05 | 64.72 | D13Mit151 | 73.1±49.1 (n=55) | 101.8±60.0 (n=116) | 108.4±70.2 (n=64) | 3.7E−03 |
|
| 1 | Non‐HDL |
| 75.67 | D1Mit270 | 696.2±341.6 (n=61) | 859.7±363.9 (n=101) | 976.9±332.6 (n=69) | 4.3E−05 |
|
| 4 | Non‐HDL | 2.51 | 13.55 | D4Mit192 | 938.6±353.6 (n=48) | 873.3±361.4 (n=106) | 730.4±344.9 (n=75) | 3.1E−03 |
|
| 12 | Non‐HDL |
| 54.04 | D12mit277 | 865.6±291.4 (n=49) | 909.7±373.4 (n=148) | 575.3±265.7 (n=38) | 1.1E−06 |
|
| 14 | Non‐HDL | 2.24 | 29.37 | D14MIT155 | 743.9±336.3 (n=68) | 869.0±359.5 (n=109) | 941.3±377.4 (n=54) | 8.1E−03 |
|
| 15 | Non‐HDL | 2.43 | 51.82 | D15Mit161 | 830.6±327.7 (n=54) | 798.9±364.9 (n=123) | 977.1±358.8 (n=56) | 7.9E−03 |
|
| X | Non‐HDL | 2.22 | 24.59 | DXMit81 | 804.2±366.2 (n=110) | 875.9±358.2 (n=116) | 1.4E−01 | |
|
| 1 | Triglyceride |
| 77.67 | D1Mit270 | 111.6±26.2 (n=61) | 135.5±41.6 (n=102) | 148.5±48.0 (n=69) | 1.9E−06 |
|
| 2 | Triglyceride | 2.62 | 49.35 | D2Mit126 | 117.4±34.5 (n=57) | 139.3±46.9 (n=124) | 135.7±35.6 (n=53) | 4.6E−03 |
|
| 16 | Triglyceride | 2.51 | 9.66 | D16Mit165 | 133.5±48.7 (n=68) | 140.9±42.7 (n=97) | 119.0±31.5 (n=62) | 3.7E−03 |
Data are mean±SD. The units for these measurements are μm2/section for atherosclerotic lesions and mg/dL for plasma lipid levels. The number in the brackets represents the number of progeny with a specific genotype at a peak marker. ANOVA was used to determine the significance level (P value) of differences for a specific phenotype among progeny with different genotypes at a specific marker. The significant LOD scores were highlighted in bold. BB indicates homozygous for B6 alleles at the linked peak marker; CC, homozygous for C3H alleles; BC, heterozygous for B6 and C3H alleles at the peak marker; QTL, quantitative trait locus; Chr, chromosome; LOD, logarithm of odds.
Figure 3.Interval mapping plot for atherosclerotic lesions on chromosome 4. The plot was created with the interval mapping function of Map Manager QTX, which includes a bootstrap test shown as a histogram estimating the CI of a QTL. Two straight vertical lines on the plot represent the genomewide significance thresholds for suggestive and significant linkage. The black line denotes the LOD score calculated at 1‐cM intervals. The blue line represents the effect of the B6 allele, and the red line represents the effect of the C3H allele. The histogram indicates the existence of 2 QTLs on the chromosome. The number in the bracket denotes the mapping distance from the centromere of a specific marker in cM. LOD indicates logarithm of odds; QTL, quantitative trait locus.
Figure 4.Genomewide scans for HDL, non‐HDL cholesterol, and triglyceride levels in the F2 population. Chromosomes 1 through 20 are represented numerically on the x axis, and the y axis represents the LOD score. Two horizontal dashed lines denote genomewide thresholds for suggestive and significant linkage. LOD indicates logarithm of odds; HDL, high‐density lipoprotein.
Figure 5.LOD score plots for HDL cholesterol levels (left) and atherosclerotic lesion size (right) on chromosome 9. Plots were created with the interval mapping function of Map Manager QTX. The histogram shown in the plots indicates the confidence interval of a QTL. The distal QTL for HDL coincided with the QTL for atherosclerotic lesions on chromosome 9. The number in the bracket denotes the cM value of a specific marker. LOD indicates logarithm of odds; QTL, quantitative trait locus; HDL, high‐density lipoprotein.
Figure 6.Scatterplots showing relationships of atherosclerotic lesion sizes with HDL and non‐HDL cholesterol levels in the F2 population. Each point represents an individual value of an F2 mouse. The correlation coefficient (r) and significance (P) are shown. Plasma levels of HDL but not non‐HDL cholesterol were significantly correlated with the sizes of atherosclerotic lesions. Top row: untransformed atherosclerotic lesion sizes in “μm2×1000”; bottom row: LN‐transformed atherosclerotic lesion sizes in “μm2”. LN indicates natural logs; HDL, high‐density lipoprotein.
Haplotype Analysis to Prioritize Candidate Genes for Atherosclerosis QTLs on Chromosomes 2 and 15
| Gene | Chromosome | Position | Low Allele | High Allele | Consequence | ||
|---|---|---|---|---|---|---|---|
| B6 | AKR/J | C3H/HeJ | DBA/2J | ||||
|
| 2 | 172847290 | G | G | c | c | 5′_UTR |
|
| 2 | 172847496 | G | G | A | A | 5′_UTR |
|
| 2 | 179177190 | C | C | T | T | 5′_UTR |
|
| 2 | 179179412 | G | G | A | A | NON_SYNONYMOUS_CODING |
|
| 2 | 179777235 | C | C | G | G | 5′_UTR |
|
| 2 | 179835661 | C | C | T | T | NON_SYNONYMOUS_CODING |
|
| 2 | 179854116 | G | G | A | A | 5′_UTR |
|
| 2 | 179913809 | C | C | A | A | NON_SYNONYMOUS_CODING |
|
| 2 | 179915098 | T | T | G | G | NON_SYNONYMOUS_CODING |
|
| 2 | 179920402 | C | C | T | T | NON_SYNONYMOUS_CODING |
|
| 2 | 179920521 | G | G | T | T | NON_SYNONYMOUS_CODING |
|
| 2 | 179921374 | T | T | C | C | NON_SYNONYMOUS_CODING |
|
| 2 | 179925043 | C | C | T | T | NON_SYNONYMOUS_CODING |
|
| 2 | 179928191 | A | A | G | G | 5′_UTR |
|
| 2 | 179928517 | G | G | A | A | 5′_UTR |
|
| 2 | 179929976 | C | C | T | T | NON_SYNONYMOUS_CODING |
|
| 2 | 179933048 | G | G | A | A | 5′_UTR |
|
| 2 | 179933067 | G | G | T | T | NON_SYNONYMOUS_CODING |
|
| 2 | 179933747 | T | T | A | A | 5′_UTR |
|
| 2 | 179933873 | G | G | A | A | NON_SYNONYMOUS_CODING |
Analysis was performed using the Sanger SNP database (http://www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/snps.pl). QTL indicates quantitative trait locus.
QTLs for Atherosclerosis and Plasma Lipids Identified in the Present Male Versus the Previously Reported Female F2 Cohort Derived From B6.Apoe−/− and C3H.Apoe−/− Mice
| Locus Name | Chr | Trait | LOD (Male) | LOD (Female) |
|---|---|---|---|---|
|
| 1 | Lesion | 2.34 | … |
|
| 1 | Lesion | 2.10 | … |
|
| 2 | Lesion |
| … |
|
| 4 | Lesion |
| … |
|
| 4 | Lesion | 2.65 | … |
|
| 7 | Lesion | 2.77 | … |
|
| 9 | Lesion |
|
|
|
| 11 | Lesion | … | 2.4 |
|
| 15 | Lesion |
| … |
|
| 1 | HDL |
| 3.0 |
|
| 3 | HDL | … | 2.3 |
|
| 8 | HDL | 2.11 | … |
|
| 9 | HDL | 3.04 | … |
|
| 9 | HDL |
| … |
|
| 12 | HDL | 2.81 | … |
|
| 13 | HDL | 3.05 | … |
|
| 1 | Non‐HDL |
|
|
|
| 4 | Non‐HDL | 2.51 | … |
|
| 5 | Non‐HDL | … | 2.2 |
|
| 9 | Non‐HDL | … | 2.5 |
|
| 12 | Non‐HDL |
| … |
|
| 14 | Non‐HDL | 2.24 | … |
|
| 15 | Non‐HDL | 2.43 | … |
|
| X | Non‐HDL | 2.22 | … |
|
| 1 | Triglyceride |
|
|
|
| 2 | Triglyceride | 2.62 | … |
|
| 8 | Triglyceride | … | 3.2 |
|
| 16 | Triglyceride | 2.51 | … |
QTL indicates quantitative trait locus; Chr, chromosome; LOD, logarithm of odds; male: the present male F2 cohort derived from B6.Apoe−/− and C3H.Apoe−/− mice; female: the female F2 cohort derived from B6.Apoe−/− and C3H.Apoe−/− mice previously reported by our group.7 The significant LOD scores were highlighted in bold.